RHHBY
Roche Holdings AG ADR

3,587
Mkt Cap
$282.58B
Volume
4.1M
52W High
$51.24
52W Low
$34.10
PE Ratio
29.89
RHHBY Fundamentals
Price
$51.22
Prev Close
$50.04
Open
$50.25
50D MA
$45.49
Beta
0.32
Avg. Volume
2.45M
EPS (Annual)
$1.47
P/B
9.06
Rev/Employee
$665,306.28
Loading...
Loading...
News
all
press releases
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
Zacks·4d ago
News Placeholder
More News
News Placeholder
Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?
Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
Zacks·4d ago
News Placeholder
What Is Driving Hologic's Strength in the US Diagnostics Market?
HOLX's Diagnostics gains accelerate as U.S. molecular testing drives growth and new Panther Fusion and Genius platform approvals widen its runway.
Zacks·4d ago
News Placeholder
Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III
RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.
Zacks·5d ago
News Placeholder
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD
Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials.
Zacks·13d ago
News Placeholder
Will Korlym Continue to Drive Corcept's Top Line in 2026?
CORT leans on rising Korlym sales while awaiting key relacorilant FDA decisions that could broaden its growth path in 2026.
Zacks·14d ago
News Placeholder
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.
Zacks·15d ago
News Placeholder
The Zacks Analyst Blog Highlights Alphabet, Roche, RTX, Crawford United and C&F Financial
Alphabet, Roche, RTX, Crawford United and C&F Financial are featured as analysts highlight strong momentum across AI, biopharma, aerospace and micro-cap industrials.
Zacks·21d ago
News Placeholder
Top Stock Reports for Alphabet, Roche & RTX
Alphabet gains momentum as AI-driven growth in Cloud, Search and YouTube fuels rising customer adoption and revenue strength.
Zacks·21d ago
News Placeholder
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
Zacks·26d ago
<
1
2
...
>

Latest RHHBY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.